Bridge to recovery with the use of left ventricular assist device and clenbuterol

Petrie, 2001, Changes in notions about heart failure, Lancet, 358, 432, 10.1016/S0140-6736(01)05664-1

Rose, 2001, Long-term mechanical left ventricular assistance for end-stage heart failure, N Engl J Med, 345, 1435, 10.1056/NEJMoa012175

Altemose, 1997, Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy, J Heart Lung Transplant, 16, 765

Zafeiridis, 1998, Regression of cellular hypertrophy after left ventricular assist device support, Circulation, 98, 656, 10.1161/01.CIR.98.7.656

Bruckner, 2001, Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support, J Heart Lung Transplant, 20, 457, 10.1016/S1053-2498(00)00321-1

Heerdt, 2000, Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure, Circulation, 102, 2713, 10.1161/01.CIR.102.22.2713

Takeishi, 2000, Alterations in Ca2+ cycling proteins, and G alpha q signaling after left ventricular assist device support in failing human hearts, Cardiovasc Res, 45, 883, 10.1016/S0008-6363(99)00415-0

Bartling B, Milting H, Schumann H. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 1999;100:II216–23

Li, 2001, Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices, Circulation, 104, 1147, 10.1161/hc3501.095215

Hetzer, 2000, Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy, J Thorac Cardiovasc Surg, 120, 843, 10.1067/mtc.2000.108931

Frazier, 1999, Left ventricular assist system as a bridge to myocardial recovery, Ann Thorac Surg, 68, 734, 10.1016/S0003-4975(99)00801-2

Hetzer, 1999, Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device, Ann Thorac Surg, 68, 742, 10.1016/S0003-4975(99)00542-1

Mancini, 1998, Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure, Circulation, 98, 2383, 10.1161/01.CIR.98.22.2383

Mann, 1998, Left ventricular assist devices and the failing heart, Circulation, 98, 2367, 10.1161/01.CIR.98.22.2367

Yacoub, 2001, A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery, Eur Heart J, 22, 534, 10.1053/euhj.2001.2613

Yacoub, 2001, A novel combination therapy to reverse end-stage heart failure, Transplant Proc, 33, 2762, 10.1016/S0041-1345(01)02183-2

Onodera, 1998, Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension, Hypertension, 32, 753, 10.1161/01.HYP.32.4.753

Houser, 1999, Function of the cardiac myocyte in the conundrum of end-stage, dilated human heart failure, Circulation, 99, 600, 10.1161/01.CIR.99.5.600

Hunter, 1999, Signaling pathways for cardiac hypertrophy and failure, N Engl J Med, 341, 1276, 10.1056/NEJM199910213411706

Brilla, 2000, Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease, Circulation, 102, 1388, 10.1161/01.CIR.102.12.1388

Zaugg, 2000, Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes, Circulation, 102, 344, 10.1161/01.CIR.102.3.344

Wong, 1998, Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features, Cardiovasc Res, 37, 115, 10.1016/S0008-6363(97)00190-9

Birks, 2001, Serum cytokines in left ventricular assist device candidates, Transplant Proc, 33, 1974, 10.1016/S0041-1345(00)02759-7

Birks EJ, Latif N, Owen V, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001;104:I233–40

Birks, 2002, Elevated toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices (LVADs), J Heart Lung Transplant, 21, 104, 10.1016/S1053-2498(01)00570-8

Douglas, 2002, Congestive heart failure and expression of myocardial urotensin II, Lancet, 359, 1990, 10.1016/S0140-6736(02)08831-1

Russell, 2001, Cardiostimulant effects of urotensin-II in human heart in vitro, Br J Pharmacol, 132, 5, 10.1038/sj.bjp.0703811

Barton PJR, Birks EJ, Felkin LE, Cullen ME, Yacoub MH. Elevated expression of extracellular matrix regulators TIMP-1 and MMP-1 in deteriorating heart failure. J Heart Lung Transplant. In press

Dollery, 1995, Matrix metalloproteinases and cardiovascular disease, Circ Res, 77, 863, 10.1161/01.RES.77.5.863

Reinhardt, 2002, Cardiac remodelling in end stage heart failure, Heart, 88, 525, 10.1136/heart.88.5.525

Peterson, 2001, Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure, Circulation, 103, 2303, 10.1161/01.CIR.103.18.2303

Buetow, 2001, High-throughput development, and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Proc Natl Acad Sci USA, 98, 581, 10.1073/pnas.98.2.581

Schneider, 2000, Chips ahoy, Circulation, 102, 3026, 10.1161/01.CIR.102.25.3026

Corbett, 1998, Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis, 19, 2031, 10.1002/elps.1150191123

Barbone, 2001, Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure, Circulation, 104, 670, 10.1161/hc3101.093903

Milting, 1999, Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy—first results of the Halle Assist Induced Recovery Study (HAIR), Thorac Cardiovasc Surg, 47, 48, 10.1055/s-2007-1013108

Bruckner, 2000, The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content, Am J Surg, 180, 498, 10.1016/S0002-9610(00)00553-5

Torre-Amione, 1999, Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support, Circulation, 100, 1189, 10.1161/01.CIR.100.11.1189

Lee, 1998, Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure, J Thorac Cardiovasc Surg, 116, 344, 10.1016/S0022-5223(98)70136-9

Goldstein, 1997, Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels, Ann Thorac Surg, 63, 971, 10.1016/S0003-4975(96)01117-4

Dipla, 1998, Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure, Circulation, 97, 2316, 10.1161/01.CIR.97.23.2316

Lowes, 2002, Myocardial gene expression in dilated cardiomyopathy treated with beta- blocking agents, N Engl J Med, 346, 1357, 10.1056/NEJMoa012630

Soloff, 1999, Atrophy of myocardium and its myocytes by left ventricular assist device, Circulation, 100, 1012, 10.1161/circ.100.9.1011/-b

Young JB. Healing the heart with ventricular assist device therapy: mechanisms of cardiac recovery. Ann Thorac Surg 2001;71:S210–9

Bersohn, 1977, Effects of physical training on end-diastolic volume and myocardial performance of isolated rat hearts, Circ Res, 40, 510, 10.1161/01.RES.40.5.510

Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation 1995;92:II483–9

Petrou, 1999, Clenbuterol increases stroke power and contractile speed of skeletal muscle for cardiac assist, Circulation, 99, 713, 10.1161/01.CIR.99.5.713

Guldner, 2000, Clenbuterol-supported dynamic training of skeletal muscle ventricles against systemic load, Circulation, 101, 2213, 10.1161/01.CIR.101.18.2213

Wong, 1997, Pharmacological modulation of pressure-overload cardiac hypertrophy, Circulation, 96, 2239, 10.1161/01.CIR.96.7.2239

Hon, 2001, Influence of clenbuterol treatment during six weeks of chronic right ventricular pressure overload as studied with pressure-volume analysis, J Thorac Cardiovasc Surg, 122, 767, 10.1067/mtc.2001.114354

Milano, 1994, Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor, Science, 264, 582, 10.1126/science.8160017

Turki, 1996, Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice, Proc Natl Acad Sci USA, 93, 10483, 10.1073/pnas.93.19.10483

Liggett, 2000, Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts, Circulation, 101, 1707, 10.1161/01.CIR.101.14.1707

Tevaearai, 2002, Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts, Circulation, 106, 124, 10.1161/01.CIR.0000020220.79105.FD

Awede BL, Thissen JP, Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am J Physiol Endocrinol Metab 2002;282:E31-7

Musaro, 2001, Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle, Nat Genet, 27, 195, 10.1038/84839